Abstract
Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Current Pharmaceutical Biotechnology
Title: Fibrinolytic Factors in Liver Fibrosis
Volume: 12 Issue: 9
Author(s): Liang-I Kang and Wendy M. Mars
Affiliation:
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Abstract: Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Export Options
About this article
Cite this article as:
Kang Liang-I and M. Mars Wendy, Fibrinolytic Factors in Liver Fibrosis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281036
DOI https://dx.doi.org/10.2174/138920111798281036 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics in the Intensive Care Unit: Focus on Potential Implications for Clinical Practice
Recent Patents on Biotechnology Corneal Changes in Diabetes Mellitus
Current Diabetes Reviews Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Mini-Reviews in Medicinal Chemistry Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report
Current Vascular Pharmacology The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Editorial
Inflammation & Allergy - Drug Targets (Discontinued) Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Obesity and Oxidative Stress: Potential Roles of Melatonin as Antioxidant and Metabolic Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy AAV-Mediated Gene Supply for Treatment of Degenerative and Neovascular Retinal Diseases
Current Gene Therapy The Role of the Immune System in the Pathogenesis of Hypertension
Current Hypertension Reviews A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) Innovative Stride to Zero Hunger Beyond 2015 in Nigeria
Recent Patents on Food, Nutrition & Agriculture Cerebral Inflow and Outflow Discrepancies in Severe Sudden Sensorineural Hearing Loss
Current Neurovascular Research Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry